LEO PHARMA A/S: Financial statements 2024
CVR: 56759514
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 12,453,000,000 and a net result of DKK -1,776,000,000 compared with DKK -3,607,000,000 the year before. That is an increase of 9.3% compared with the year before. The profit margin was -14.3%. Equity in the 2024 report amounted to DKK 2,704,000,000. The solvency ratio was 13.4%. The company had 4,184 employees in the financial year.
- Revenue
- DKK 12,453,000,000
- Gross Profit
- DKK 7,518,000,000
- Profit/Loss
- DKK -1,776,000,000
- Equity
- DKK 2,704,000,000
- Total Assets
- DKK 20,151,000,000
- Employees
- 4,184
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 12.5 mia. | 7.5 mia. | -1.8 mia. | 2.7 mia. | 4184 |
| 2023 | 11.4 mia. | 7.1 mia. | -3.6 mia. | 4.5 mia. | 4490 |
| 2022 | 10.6 mia. EUR | 6 mia. EUR | -4.1 mia. EUR | 1.9 mia. EUR | 5252 |
| 2021 | 10 mia. | 6 mia. | -4.9 mia. | 5.5 mia. | - |
| 2020 | 10.1 mia. | 6.8 mia. | -951 mio. | 6.9 mia. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
LEO PHARMA A/S has won the tender "Amgros 2025 1.356.a" issued by Amgros I/S worth 4,530,400,000 DKK.
LEO PHARMA A/S has won the tender "Amgros 2025 1.1471.a" issued by Amgros I/S worth 550,200,000 DKK.
As of July 31, 2024, Johannes Gerardus Joseph van de Winkel has left the board of directors of LEO PHARMA A/S.
As of April 24, 2024, Raj Rashmikant Shah has joined the board of directors of LEO PHARMA A/S.
As of April 24, 2024, Jonas Wilhelm Agnblad has left the board of directors of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2023. Revenue came to DKK 11,392,000,000, and the net result was DKK -3,607,000,000.
As of March 1, 2024, Thomas Christian Facius has joined the board of directors of LEO PHARMA A/S.
As of March 1, 2024, Henrik Bo Andersson has joined the board of directors of LEO PHARMA A/S.
As of March 1, 2024, Karin Attermann has left the board of directors of LEO PHARMA A/S.
As of February 29, 2024, Henrik Bo Andersson has left the board of directors of LEO PHARMA A/S.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.